Bioluminescent Study of the Distribution of High-Molecular-Weight Protein Fraction of Cellex Daily Preparation in the Brain after Intranasal Administation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Permeability of the blood—brain barrier for protein fractions 50-100 kDa (PF50–100) of Cellex Daily preparation labeled with fluorescent tracer FITC and non-conjugated FITC were compared after intranasal administration of the preparations to healthy rats. Fluorimetrical analysis of the serum and cerebrospinal fluid samples showed that Cellex Daily PF50–100-FITC administered intranasally penetrated into the blood and cerebrospinal fluid with maximum accumulation in 2 h after administration and persists in the circulation for 24 h probably due to binding with plasma proteins. The differences in the kinetic profile of PF50–100-FITC and free FITC indirectly suggest that the major part of the preparation is not degraded within 24 h and FITC is probably not cleaved from the protein components of the preparation. In vivo fluorescence analysis showed significant fluorescent signal in the olfactory bulbs in 6 h after intranasal administration; hence, the preparation administered via this route can bypass the blood—brain barrier. Scanning laser confocal microscopy of rat brain sections confirmed penetration of the high-molecular weight protein fraction PF50–100-FITC into CNS structures. The most pronounced accumulation of the labeled drug was observed in the olfactory bulb in 6 and 12 h after administration. In contrast to free FITC administered in the control group, significant accumulation of PF50–100-FITC in the olfactory cortex and frontal cortex neurons with functionally active nuclei was observed in 6, 12 and 24 h after intranasal administration.

About the authors

V. P. Baklaushev

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency

Author for correspondence.
Email: serpoff@gmail.com
Russian Federation, Moscow

G. M. Yusubalieva

V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Russian Federation, Moscow

M. S. Burenkov

Farm-Sintez Company

Email: serpoff@gmail.com
Russian Federation, Moscow

P. A. Mel’nikov

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency; V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Russian Federation, Moscow; Moscow

E. A. Bozhko

Farm-Sintez Company

Email: serpoff@gmail.com
Russian Federation, Moscow

G. A. Mentyukov

Farm-Sintez Company

Email: serpoff@gmail.com
Russian Federation, Moscow

L. S. Lavrent’eva

Farm-Sintez Company

Email: serpoff@gmail.com
Russian Federation, Moscow

M. A. Sokolov

Farm-Sintez Company

Email: serpoff@gmail.com
Russian Federation, Moscow

V. P. Chekhonin

V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation; N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation

Email: serpoff@gmail.com
Russian Federation, Moscow; Moscow


Copyright (c) 2017 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies